Madrigal Pharmaceuticals IncNASDAQ:MDGL
- LAST PRICE329.2300
- TODAY'S CHANGE (%)-2.0900 (-0.6308%)
- Bid / Lots328.5700/ 8
- Ask / Lots329.8900/ 8
- Open / Previous Close331.0000 / 331.3200
- Day Range
- 52 Week Range
- Volume251,058
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDGL |
|---|---|---|
| 09:32 ET | 4169 | 332.91 |
| 09:33 ET | 250 | 331.71 |
| 09:35 ET | 2498 | 331.96 |
| 09:37 ET | 975 | 330.29 |
| 09:39 ET | 1774 | 329.96 |
| 09:42 ET | 3500 | 330.37 |
| 09:44 ET | 1456 | 328.1 |
| 09:46 ET | 4676 | 324.89 |
| 09:48 ET | 1585 | 322.54 |
| 09:50 ET | 2200 | 325.36 |
| 09:51 ET | 1187 | 326.05 |
| 09:53 ET | 800 | 325.79 |
| 09:55 ET | 3529 | 323.23 |
| 09:57 ET | 4504 | 318.84 |
| 10:00 ET | 7435 | 317.53 |
| 10:02 ET | 12227 | 318.9 |
| 10:04 ET | 2825 | 317.1807 |
| 10:06 ET | 2160 | 317.17 |
| 10:08 ET | 4384 | 319 |
| 10:09 ET | 1303 | 317.93 |
| 10:11 ET | 6108 | 318.56 |
| 10:13 ET | 5103 | 321.98 |
| 10:15 ET | 1905 | 320.985 |
| 10:18 ET | 300 | 320.985 |
| 10:20 ET | 3819 | 322.765 |
| 10:22 ET | 2420 | 322.31 |
| 10:24 ET | 300 | 321.72 |
| 10:26 ET | 1423 | 321.875 |
| 10:27 ET | 2237 | 320.48 |
| 10:29 ET | 900 | 320.94 |
| 10:31 ET | 2000 | 322.3 |
| 10:33 ET | 1100 | 321.31 |
| 10:36 ET | 600 | 323.43 |
| 10:38 ET | 200 | 323.57 |
| 10:40 ET | 7614 | 326.655 |
| 10:42 ET | 1500 | 327.6 |
| 10:44 ET | 3293 | 327.85 |
| 10:45 ET | 440 | 327.995 |
| 10:47 ET | 1200 | 327.56 |
| 10:49 ET | 400 | 327.885 |
| 10:51 ET | 5373 | 328.94 |
| 10:54 ET | 300 | 329.53 |
| 10:56 ET | 601 | 329.53 |
| 10:58 ET | 800 | 329 |
| 11:00 ET | 200 | 329.65 |
| 11:02 ET | 7736 | 329.87 |
| 11:03 ET | 1509 | 329.16 |
| 11:05 ET | 200 | 329.705 |
| 11:07 ET | 3529 | 330.73 |
| 11:09 ET | 3720 | 329.78 |
| 11:12 ET | 700 | 329.23 |
Today
Nov 1, 2024
DJ Madrigal Pharmaceuticals Is Maintained at Buy by UBS, from 2:37PM ET on Friday Nov 01, 2024 by Dow Jones
2:37PM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates, from 7:01AM ET on Thursday Oct 31, 2024 by Dow Jones
7:01AM ET on Thursday Oct 31, 2024 by Dow Jones*DJ Madrigal Pharmaceuticals 3Q Loss/Shr $4.92 >MDGL, from 7:01AM ET on Thursday Oct 31, 2024 by Dow Jones
7:01AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
Madrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting(R), from 8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Madrigal Pharmaceuticals Inc | 7.2B | -13.1x | --- |
Viking Therapeutics Inc | 7.0B | -71.0x | --- |
Cytokinetics Inc | 6.1B | -9.6x | --- |
Nuvalent Inc | 5.8B | -32.0x | --- |
Avidity Biosciences Inc | 5.3B | -14.8x | --- |
Crinetics Pharmaceuticals Inc | 5.1B | -15.0x | --- |
Company Information
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Contact Information
- Headquarters
- 200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN, PA, United States 19428-2978
- Phone
- 404-380-9263
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Julian Baker
- President, Chief Executive Officer, Director
- Bill Sibold
- Chief Financial Officer, Senior Vice President
- Mardi Dier
- President of Research and Development, Chief Medical Officer, Director
- Rebecca Taub
- Senior Vice President - Clinical Development
- Michael Charlton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.2B |
|---|---|
Revenue (TTM) | $76.8M |
Shares Outstanding | 21.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.50 |
EPS | $-25.07 |
Book Value | $20.39 |
P/E Ratio | -13.1x |
Price/Sales (TTM) | 94.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -713.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
